Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirna-027 Dose Escalation in AMD
NCT00363714Phase 2Completed
- Sponsor
- Allergan
- Start
- Nov 2004
- Primary completion
- Apr 2007
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, open-label trial of Sirna-027 in age-related macular degeneration (AMD) (6 arms), sponsored by Allergan. Primary endpoint: Adverse Events at 3 months. Started Nov 2004; status: completed.
02
Drugs
Sirna-027
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00363714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363714.